顺尔宁联合舒利迭治疗小儿咳嗽变异性哮喘的疗效分析

目的：探讨顺尔宁联合舒利迭治疗小儿咳嗽变异性哮喘（CVA）的临床疗效。方法将85例CVA患儿分为观察组43例和对照组42例，观察组给予顺尔宁联合舒利迭治疗，对照组给予舒利迭治疗，观察两组疗效。结果观察组临床症状、肺功能改善及近期疗效方面均优于对照组（P 〈0.05）；患儿1年复发率明显低于对照组（P 〈0.05）；两组不良反应无显著差异（P〉0.05）。结论顺尔宁联合舒利迭治疗CVA疗效显著、症状改善明显、复发率低等，且安全可靠，值得推广。

Effects of Montelukast and Seretide in Treating Cough Variant Asthma of Children

Objective Discuss the clinical effects of Montelukast and Seretide in treating cough variant asthma of children（CVA）. Methods Divide the 85 CVA patients into the groups of observation（43） and control（42）. The observation group is treated with both Montelukast and Seretide, while the other group is treated with only Seretide. Observe effects of the treatment among both groups. Results The observation group is better than the control group in terms of the clinical symptoms, improvement in lung function, and potencies achieved recently（P 〈0.05）. The recurrence rate of the observation group within one year is 11.63%, obviously lower than 33.33% of the control group（P 〈0.05）. No significant differences in adverse reaction between the two groups are observed（P 〉0.05）. Conclusion Treating CVA with both Montelukast and Seretide can achieve remarkable curative effects, considerable symptom improvements, low recurrence rate, and high safety and reliability, thus it is qualified for wider uses.